COVID-19 IN CHILDREN IN NIGER, 2020

NCT ID: NCT05886179

Last Updated: 2023-06-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

572 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-25

Study Completion Date

2021-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

On January 30, 2020, the WHO declared COVID-19 a global health emergency. Children were affected with less severe forms. Niger had implemented measures in a context where children are a source of contamination. The objective was to determine the factors associated with COVID-19 in children in Niger from February to August 2020 through an analysis of the national database.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We conducted an analytical cross-sectional study including all COVID-19 suspects in the database. We used Excel and Epi Info 7.2.4. software for data extraction and analysis. Frequencies and proportions were calculated, we estimated in a logistic regression the OR of association with their 95% confidence interval, the factors associated with COVID-19 at the threshold of p\<0.05.

Results: Of 572 notified suspected COVID-19 cases in children aged 0-15 years, 11.36% were positive. The median age of infected children was 10 years \[IQR: 5- 13 years\]. The sex ratio of males to females was 2.1. Children aged 11-15 years were 49.2%, 61.5% resided in Niamey, 4.6% had comorbidities. The notion of travel was 12.3% and 40% had a notion of contact, 24.4% had a fever, 23.2% had a cough, 18% were hospitalized and the case fatality was 1.5%. In etiological analysis, the factors associated with COVID-19 were sex ORa= 0.51 \[0.28-0.93\] p=0.028, the presence of symptoms ORa= 2.29 \[1.23-4.25\] p=0.008 and the notion of contact ORa= 0.32 \[0.13-0.77\] p=0.011.

exposed children were sensitive to COVID-19, all age groups were affected with a male predominance. We recommend barrier measures adapted to young people, early detection and management of infected children.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

to Contribute to a Better Control of COVID-19 in Children in Niger

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cross-sectional study

analytical cross-sectional study with retrospective collection of epidemiological surveillance data on COVID-19 in Niger.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children aged 0-15 years suspected of having COVID-19 whose data were in the DSRE database were included

Exclusion Criteria

* Children whose data is not complete
Minimum Eligible Age

0 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre de Recherche Médicale et Sanitaire

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

IDE AMADOU Habibatou

Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IDE AMADOU Habibatou

Niamey, , Niger

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Niger

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CERMES

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Chemoprevention Efficacy Study Nigeria
NCT05979896 UNKNOWN PHASE4
Febrile Illness in Guinea
NCT06122259 RECRUITING
Home Management of Malaria and Pneumonia
NCT02151578 COMPLETED PHASE4
Malaria Prevalence in Children
NCT00322816 COMPLETED